Aclarion (ACON) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Executive summary
The annual meeting is scheduled for June 4, 2026, with voting on director elections, auditor ratification, and an amendment to the equity incentive plan.
Only stockholders of record as of April 10, 2026, are eligible to vote, with 2,462,250 shares outstanding.
Proxy materials and annual reports are available online and by request.
Voting matters and shareholder proposals
Seven director nominees are up for election to serve until the 2027 annual meeting.
Ratification of Haynie & Company as independent auditor for fiscal year ending December 31, 2026.
Approval sought for an amendment to the 2022 Equity Incentive Plan, increasing the share reserve and annual grant limits.
Shareholders may submit proposals for the 2027 meeting by December 28, 2026, for inclusion in proxy materials.
Board of directors and corporate governance
The board consists of seven members, with a majority deemed independent under Nasdaq and SEC rules.
Three standing committees: audit, compensation, and nominating/corporate governance, each with independent chairs.
The nominating committee values diversity and considers stockholder recommendations for director nominees.
Board and committees met regularly in 2025, with all directors attending at least 75% of meetings.
A code of business conduct and ethics applies to all directors, officers, and employees.
Latest events from Aclarion
- Shareholders will vote on director elections, auditor ratification, and a major equity plan amendment.ACON
Proxy filing3 Apr 2026 - Revenue up 65.6% to $75.7K; net loss $7.2M; $22.6M raised in 2025, $10.4M in 2026.ACON
Q4 202518 Mar 2026 - Non-invasive spinal diagnostics see clinical, commercial, and reimbursement momentum in key markets.ACON
Investor Update23 Jan 2026 - Non-invasive lumbar disc diagnostics show strong outcomes and payer traction, driving expansion.ACON
Investor Update12 Jan 2026 - Shelf registration enables up to $50M in offerings for AI-driven spine diagnostics in a high-need market.ACON
Registration Filing16 Dec 2025 - Healthcare tech firm targets $50M raise amid Nasdaq risks, leveraging patented MRS diagnostics.ACON
Registration Filing16 Dec 2025 - AI-driven diagnostics firm faces Nasdaq risks, offers 27.5M shares for resale, no direct proceeds.ACON
Registration Filing16 Dec 2025 - Up to $150M in securities to fund AI-driven diagnostics for back and neck pain; high risk, high potential.ACON
Registration Filing16 Dec 2025 - Key votes include director elections, auditor ratification, a reverse split, and equity plan changes.ACON
Proxy Filing2 Dec 2025